The Importance of HLA Assessment in “Off-the-Shelf” Allogeneic Mesenchymal Stem Cells Based-Therapies

Kot, Marta; Baj‐Krzyworzeka, Monika; Szatanek, Rafał; Musiał-Wysocka, Aleksandra; Suda-Szczurek, Magdalena; Majka, Marcin

doi:10.3390/ijms20225680

Cited by 66 publications

(74 citation statements)

References 151 publications

(226 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This question is still under debate. While some studies show that allogeneic MSCs can induce allorecognition responses, which include the expansion of immune cell subpopulations and detectable levels of allo-specific antibodies (Schnabel et al 2014;Wang et al 2019), a recent review shows that, although MSCs are not as immuneprivileged as previously though, evidence from clinical trials suggest that allogeneic MSCs transplantation is safe and can be used as an "off-the-shelf" medical product (Kot et al 2019).…”

Section: Discussionmentioning

confidence: 99%

Coronary corium, a new source of equine mesenchymal stromal cells

et al. 2020

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) have attracted great attention for therapeutic applications. Since cells derived from different tissues have different properties, using the right tissue source may impact their efficiency in regenerative medicine. This study describes for the first time the isolation and characterization of MSCs derived from the equine coronary corium, which may be useful for treating diseases such as laminitis. Seven coronary corium samples were used for isolation of cells (ccMSCs). Adherent cells were characterized for morphology, immunophenotype, proliferation and differentiation potential, in vitro migration and colony-forming capacity. The cells displayed the characteristic fibroblastoid morphology, with population doubling time increasing until passage 7 and reaching a plateau in passage 10. Cells were negative for CD14 and CD45, and positive for CD73 and CD90. ccMSCs showed chondrogenic and osteogenic, but not adipogenic differentiation, and migrated with nearly total closing of the empty area in 48 h, in the scratch assay. The clonogenic potential was in average 18% to 23%. This study describes for the first time the establishment of mesenchymal stromal cell cultures from the equine coronary corium. The results are similar to MSCs isolated from many other equine tissues, except for restricted differentiation potential. As coronary corium stem cell regulation may contribute to the pathogenesis of equine chronic laminitis, the use of ccMSCs in cell therapy for this significantly debilitating disease should be further investigated.

show abstract

Section: Discussionmentioning

confidence: 99%

Coronary corium, a new source of equine mesenchymal stromal cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, this proposal leads to the unsolved question of the MSC immunogenicity. It is well known that there is immune activation of host cytotoxicity mediated by complement, NK cells and/or cytotoxic T cells ( Noone et al, 2013 ; Ankrum et al, 2014 ; Berglund et al, 2017 ; Kot et al, 2019 ). In fact, syngeneic MSCs persist for more than 200 days, whereas allogeneic cells rapidly disappear ( Eliopoulos et al, 2005 ).…”

Section: Allogeneic or Autologous Mesenchymal Stromal Cells For Theramentioning

confidence: 99%

The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy

García‐Bernal

García-Arranz

Yáñez

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) currently constitute the most frequently used cell type in advanced therapies with different purposes, most of which are related with inflammatory processes. Although the therapeutic efficacy of these cells has been clearly demonstrated in different disease animal models and in numerous human phase I/II clinical trials, only very few phase III trials using MSCs have demonstrated the expected potential therapeutic benefit. On the other hand, diverse controversial issues on the biology and clinical applications of MSCs, including their specific phenotype, the requirement of an inflammatory environment to induce immunosuppression, the relevance of the cell dose and their administration schedule, the cell delivery route (intravascular/systemic vs. local cell delivery), and the selected cell product (i.e., use of autologous vs. allogeneic MSCs, freshly cultured vs. frozen and thawed MSCs, MSCs vs. MSC-derived extracellular vesicles, etc.) persist. In the current review article, we have addressed these issues with special emphasis in the new approaches to improve the properties and functional capabilities of MSCs after distinct cell bioengineering strategies.

show abstract

“…This may be considered a step forward in development of what is called "off-shelf stem cells drugs." A very recent review addressed this issue and the authors declared that MSCs can effectively be used as an allogenic off-shelf drug despite special concerns of their HLA make up (Kot et al, 2019). This notion requires further investigations and considerations of the challenges that will be further discussed in this review.…”

Section: Clinical Application Of Wj-mscs In Diabetesmentioning

confidence: 99%

Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges

Kamal

Kassem

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Diabetes mellitus (DM) is an alarming metabolic disease in which insulin secreting β-cells are damaged to various extent. Unfortunately, although currently available treatments help to manage the disease, however, patients usually develop complications, as well as decreased life quality and increased mortality. Thus, efficient therapeutic interventions to treat diabetes are urgently warranted. During the past years, mesenchymal stem cells (MSCs) have made their mark as a potential weapon in various regenerative medicine applications. The main fascination about MSCs lies in their potential to exert reparative effects on an amazingly wide spectrum of tissue injury. This is further reinforced by their ease of isolation and large ex vivo expansion capacity, as well as demonstrated multipotency and immunomodulatory activities. Among all the sources of MSCs, those isolated from umbilical cord-Wharton's jelly (WJ-MSCs), have been proved to provide a great source of MSCs. WJ-MSCs do not impose any ethical concerns as those which exist regarding ESCs, and represent a readily available non-invasive source, and hence suggested to become the new gold standard for MSC-based therapies. In the current review, we shall overview achievements, as well as challenges/hurdles which are standing in the way to utilize WJ-MSCs as a novel efficient therapeutic modality for DM.

show abstract

The Importance of HLA Assessment in “Off-the-Shelf” Allogeneic Mesenchymal Stem Cells Based-Therapies

Cited by 66 publications

References 151 publications

Coronary corium, a new source of equine mesenchymal stromal cells

Coronary corium, a new source of equine mesenchymal stromal cells

The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy

Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges

Contact Info

Product

Resources

About